Nomura Holdings Inc. Invests $463,000 in China Biologic Products, Inc. (NASDAQ:CBPO)

Nomura Holdings Inc. acquired a new stake in China Biologic Products, Inc. (NASDAQ:CBPO) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 4,623 shares of the biopharmaceutical company’s stock, valued at approximately $463,000.

Several other institutional investors have also recently modified their holdings of CBPO. FMR LLC increased its stake in shares of China Biologic Products by 27.5% in the first quarter. FMR LLC now owns 1,880,549 shares of the biopharmaceutical company’s stock worth $188,300,000 after buying an additional 406,105 shares during the last quarter. BlackRock Inc. increased its stake in shares of China Biologic Products by 694.1% in the first quarter. BlackRock Inc. now owns 1,508,096 shares of the biopharmaceutical company’s stock worth $151,007,000 after buying an additional 1,318,183 shares during the last quarter. FIL Ltd increased its stake in shares of China Biologic Products by 3.2% in the first quarter. FIL Ltd now owns 878,769 shares of the biopharmaceutical company’s stock worth $87,991,000 after buying an additional 27,493 shares during the last quarter. Hermes Investment Management Ltd. increased its stake in shares of China Biologic Products by 91.6% in the first quarter. Hermes Investment Management Ltd. now owns 631,224 shares of the biopharmaceutical company’s stock worth $63,204,000 after buying an additional 301,828 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of China Biologic Products by 5.9% in the first quarter. Bank of New York Mellon Corp now owns 563,527 shares of the biopharmaceutical company’s stock worth $56,426,000 after buying an additional 31,297 shares during the last quarter. 74.29% of the stock is currently owned by institutional investors.

China Biologic Products, Inc. (NASDAQ:CBPO) opened at 103.01 on Wednesday. The stock’s 50 day moving average is $108.90 and its 200-day moving average is $108.90. China Biologic Products, Inc. has a 52 week low of $96.99 and a 52 week high of $137.38. The stock has a market capitalization of $2.80 billion, a PE ratio of 26.68 and a beta of 1.74.

COPYRIGHT VIOLATION NOTICE: “Nomura Holdings Inc. Invests $463,000 in China Biologic Products, Inc. (NASDAQ:CBPO)” was originally posted by BBNS and is owned by of BBNS. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/nomura-holdings-inc-invests-463000-in-china-biologic-products-inc-cbpo-updated-updated-updated/1072653.html.

A number of equities research analysts recently commented on the stock. Goldman Sachs Group, Inc. (The) began coverage on shares of China Biologic Products in a research report on Tuesday, May 30th. They issued a “neutral” rating for the company. Zacks Investment Research cut shares of China Biologic Products from a “hold” rating to a “sell” rating in a report on Wednesday, April 26th. BidaskClub cut shares of China Biologic Products from a “hold” rating to a “sell” rating in a report on Sunday. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $140.00 target price on shares of China Biologic Products in a report on Monday, June 12th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $132.00.

In related news, insider Zhijing Cbpo Liu sold 7,500 shares of the stock in a transaction that occurred on Tuesday, May 9th. The shares were sold at an average price of $116.49, for a total transaction of $873,675.00. Following the completion of the sale, the insider now directly owns 10,969 shares of the company’s stock, valued at $1,277,778.81. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.73% of the stock is owned by corporate insiders.

About China Biologic Products

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment.

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana
Mike Trout Returns from Injury With Single and Stole Base
Mike Trout Returns from Injury With Single and Stole Base
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana
Players Know They Could Go From All-Star Game to Trade Block
Players Know They Could Go From All-Star Game to Trade Block


Leave a Reply

 
© 2006-2017 BBNS.